---
title: "Stifel Nicolaus Remains a Buy on Viking Therapeutics (VKTX)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284804524.md"
description: "Stifel Nicolaus analyst Annabel Samimy has maintained a Buy rating on Viking Therapeutics (VKTX) with a price target of $95.00. The analyst consensus for VKTX is a Strong Buy, with an average price target of $93.27. Samimy has an average return of 16.0% and a 50.00% success rate on her stock recommendations, focusing on the Healthcare sector."
datetime: "2026-04-30T15:26:47.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284804524.md)
  - [en](https://longbridge.com/en/news/284804524.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284804524.md)
---

# Stifel Nicolaus Remains a Buy on Viking Therapeutics (VKTX)

In a report released today, Annabel Samimy from Stifel Nicolaus maintained a Buy rating on Viking Therapeutics, with a price target of $95.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Samimy covers the Healthcare sector, focusing on stocks such as Trevi Therapeutics, Ligand Pharma, and Viking Therapeutics. According to TipRanks, Samimy has an average return of 16.0% and a 50.00% success rate on recommended stocks.

Currently, the analyst consensus on Viking Therapeutics is a Strong Buy with an average price target of $93.27.

### Related Stocks

- [VKTX.US](https://longbridge.com/en/quote/VKTX.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [SF.US](https://longbridge.com/en/quote/SF.US.md)
- [TRVI.US](https://longbridge.com/en/quote/TRVI.US.md)
- [LGND.US](https://longbridge.com/en/quote/LGND.US.md)
- [SF-C.US](https://longbridge.com/en/quote/SF-C.US.md)
- [SFB.US](https://longbridge.com/en/quote/SFB.US.md)
- [SF-B.US](https://longbridge.com/en/quote/SF-B.US.md)
- [SF-D.US](https://longbridge.com/en/quote/SF-D.US.md)

## Related News & Research

- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [Relay drug shows early promise against rare blood vessel diseases](https://longbridge.com/en/news/287094432.md)
- [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md)
- [Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026 | VKTX Stock News](https://longbridge.com/en/news/285192819.md)